Medtronic's 4th-quarter profits plunged nearly 54% on its $750 million settlement with Edwards Lifesciences over replacement heart valve technology.
A New England Journal of Medicine report on higher-than-expected blood clot rates for Thoratec's HeartMate II implantable heart pump took market share during the 1st quarter, company officials said today.
A New England Journal of Medicine report last year detailing sharp increases in the rate of blood clots helped take market share away from Thoratec (NSDQ:THOR) and its HeartMate II implantable heart pump, company officials said yesterday.
A massive restructuring at Siemens aims to establish its healthcare business, which posted fiscal 2nd-quarter profit growth of 19%, as a stand-alone division could be the 1st step toward a spinout for Siemens Healthcare.
Siemens (NYSE:SI) unveiled a massive reorganization today that could be the 1st step toward a spinout for its healthcare business, which posted 19% profit growth during Siemens' fiscal 2nd quarter.
CareFusion touts strong sales of its ChloraPrep antiseptic in the months following a $41 million settlement over past sales practices and relationships with healthcare professionals.
California-based CareFusion (NYSE:CFN) posted a strong 3rd quarter and narrowed its full-year sales outlook, touting strong sales growth, even for its controversial ChloraPrep surgical wipes.
Volcano Corp. says it's finished with the reorganization and expansion of its U.S. sales force, having added 20 positions.
Volcano (NSDQ:VOLC) said it's added 20 positions to its U.S. sales force, capping a reorganization and expansion plan aimed at driving organic growth.
Globus Medical reports another strong quarter, with sales and profits up following the company's entry to the robotic surgery market.
Globus Medical (NYSE:GMED) got some Wall Street love after reporting a strong 1st quarter, during which the company notched the acquisition of Excelsius Surgical.
Haemonetics will close a 270-employee manufacturing facility in Scotland and repurchase up to $100 million of its own shares after posting a tough quarter that missed analysts' expectations.
Massachusetts-based Haemonetics (NYSE:HAE) is making some big moves after posting a tough 4th quarter and projecting a dim outlook for the fiscal year ahead.